Pharming Group N.V. ADR Quality Score
PHAR
Business quality is the primary weakness (avg 30/100). Growth is the relative bright spot.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Above 30x, priced for sustained outperformance
25–30x, paying up for cash generation
Above 10% CAGR, strong compounder
Above 10% CAGR, strong compounder
Business Quality & Capital Allocation
Heavy dilution above 5%
Modest contraction, within normal range
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
Pharming Group N.V. ADR (PHAR) quality: score, margins and returns
Pharming Group N.V. ADR (PHAR) scores 56/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 3.4% operating margins and 2.9% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Pharming Group N.V. ADR (PHAR) a high-quality business?+
Pharming Group N.V. ADR scores 56 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 3.4% operating margin and a 2.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Pharming Group N.V. ADR's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from PHAR's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Pharming Group N.V. ADR scores well and where it falls behind.
What is Pharming Group N.V. ADR's return on invested capital (ROIC)?+
Pharming Group N.V. ADR earns about 2.9% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to PHAR's margins and growth on this scorecard to judge durability.
How profitable is Pharming Group N.V. ADR?+
Pharming Group N.V. ADR runs an operating margin of about 3.4% and a net margin of about 2.5%. Revenue has grown at roughly 16.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with PHAR
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PHAR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.